^
Association details:
| Biomarker: | HLA-A*02 + MAGEA4 expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | uzatresgene autoleucel (ADP-A2M4CD8) (MAGE-A4 inhibitor, CD8 T-cell agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
540P - Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8a co-receptor and an affinity optimized TCR targeting MAGE-A4
Published date:
09/13/2021
Excerpt:
First-in-human trial in HLA-A*02 positive patients (pts) with advanced cancers expressing MAGE-A4 antigen....18 pts (10 male, 8 female) were treated with ADP-A2M4CD8... Of the 15 evaluable pts, 13 had evidence of disease control and there were RECIST responses in several solid tumor types....Emerging efficacy data remain encouraging with the majority of pts experiencing disease control and RECIST responses in several solid tumor types.
Trial ID:
